MALARIA ON THE THAI-BURMESE BORDER - TREATMENT OF 5192 PATIENTS WITH MEFLOQUINE-SULFADOXINE-PYRIMETHAMINE
- 1 January 1987
- journal article
- research article
- Vol. 65 (6) , 891-896
Abstract
Multidrug-resistant falciparum malaria is a major health problem along the Thai-Burmese border. From July 1985 until December 1986 a total of 5192 patients with falciparum malaria (1734 males, 3458 females) from this area were given supervised treatment with the combination mefloquine-sulfadoxine-pyrimethamine (MSP). The radical curve rate assessed 21 days after drug administration, was 98.4% for the first 1975 patients, and 98.8% when assessed at 28 days for the remaining 3217 patients. In 3.8% of cases, parasites were still detected in peripheral blood smears on day 7 after treatment but this had fallen to 0.27% by day 9. Adverse reactions among the first 1975 patients were: vertigo (7.5% of patients), vomiting (5.8%), epigastric pain (0.6%), and transient confusional state (one case). MSP is an effective and well-tolerated drug for the treatment of drug-resistant falciparum malaria; however, delayed parasite clearance may give a false impression of RII resistance.This publication has 6 references indexed in Scilit:
- Severe Cutaneous Reactions among American Travelers Using Pyrimethamine-Sulfadoxine (Fansidar®) for Malaria ProphylaxisThe American Journal of Tropical Medicine and Hygiene, 1986
- Treatment of Falciparum Malaria with Quinine and Tetracycline or Combined Mefloquine/Sulfadoxine/Pyrimethamine on the Thai-Kampuchean BorderThe American Journal of Tropical Medicine and Hygiene, 1986
- TRIALS OF MEFLOQUINE IN VIVAX AND OF MEFLOQUINE PLUS 'FANSIDAR' IN FALCIPARUM MALARIAThe Lancet, 1985
- A PHASE-II CLINICAL-TRIAL OF MEFLOQUINE IN PATIENTS WITH CHLOROQUINE-RESISTANT FALCIPARUM-MALARIA IN THAILAND1983
- Recent advances in malaria with special reference to Southeast Asia.1982
- The inhibitory effect of a drug combination on the development of mefloquine resistance inPlasmodium bergheiPathogens and Global Health, 1980